AMSTERDAM, the Netherlands, Jan. 6, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial through a press release at 06:00 EST/12:00 CET on January 7, 2016. The Company’s management team will hold a conference call and webcast at 08:30 EST/14:30 CET after the press release has been issued to discuss the update.
The conference call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code: 1640435. The webcast, including accompanying slides also available as a PDF file, can be accessed through the link displayed in the “Events” section on the “Media” page of the uniQure website at http://www.uniqure.com/news/calendar-of-events/. The webcast replay will be available for at least 72 hours following the call.
Conference Call Numbers
| London, United Kingdom: | +44 (0) 20 3427 1906 | |
| New York, United States of America: | +1 212 444 0412 | |
| Berlin, Germany: | +49 (0) 30 3001 90534 | |
| Amsterdam, Netherlands: | +31 (0) 20 716 8296 | |
| Paris, France: | +33 (0) 1 76 77 22 31 | |
| Milan, Italy: | +39 02 3859 1420 | |
| Brussels, Belgium: | +32 (0) 2 402 3092 | |
| Montreal, Canada: | +1 514 841 2154 | |
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT: uniQure: Direct: +31 20 240 6110 Main: +31 20 240 6000 e.mulder@uniQure.com Media inquiries: Gretchen Schweitzer MacDougall Biomedical Communications Direct: +49 172 861 8540 Main: +49 89 2424 3494 or +1 781 235 3060 gschweitzer@macbiocom.com
